FDA makes distinction between point-of-care and OTC glucose monitors

Two proposals from the FDA outline separate guidelines for over-the-counter blood glucose monitors and those used at the point of care. The guidelines propose, among other things, that both devices be required to adopt strict disinfectant regimens, but with an emphasis on infection control for po...

Share

This news summary appeared in DiabetesPro SmartBrief on 01/13/2014
Click here to view the full issue.


View the original article:
MedPage Today (free registration)

Want to see more news summaries?
Sign up for DiabetesPro SmartBrief

DiabetesPro SmartBrief is a FREE, daily email newsletter that summarizes the day's top industry news from hundreds of sources. Each day, subscribers receive 8-10 headlines and news summaries like the one to the left
Sign up:
About SmartBrief
SmartBrief is the leading online publisher of targeted business news and information by industry. By combining technology and editorial expertise, SmartBrief filters thousands of sources daily to deliver the most relevant industry news in partnership with more than 180 trade associations, professional societies nonprofits and corporate entities